MedinCell enters into a technology agreement for long-acting injectable products

MedinCell and Sandoz will develop and commercialize long-acting injectable products based on BEPO technology with a primary focus on oncology.

Both parties will join forces to develop and commercialize long-acting injectables with a primary focus on oncology. The first product has been selected and development efforts are underway.

Under the agreement, target APIs will be formulated using the proprietary MedinCell BEPO technology platform. BEPO may allow less frequent drug administration and potentially improved patient tolerability, which may reduce both direct and indirect drug costs.

The alliance will benefit from BEPO’s disruptive characteristics: superior controlled drug release, low cost of goods and rapid formulation development. BEPO’s versatile platform is compatible with many small molecules, peptides and biologics. Both parties will have access to GMP-grade polymers through the newly formed joint venture between MedinCell S.A. and Corbion N.V., CM Biomaterials.